Adicet Bio, Inc. (ACET)

NASDAQ: ACET · IEX Real-Time Price · USD
20.19
+0.93 (4.83%)
Dec 5, 2022 4:00 PM EST - Market closed
4.83%
Market Cap 825.32M
Revenue (ttm) 30.46M
Net Income (ttm) -55.73M
Shares Out 41.64M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 639,770
Open 19.42
Previous Close 19.26
Day's Range 18.86 - 20.9
52-Week Range 9.88 - 21.87
Beta 1.71
Analysts Buy
Price Target 28.65 (+41.9%)
Earnings Date Nov 9, 2022

About ACET

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company a... [Read more]

Industry Health Care Providers & Services
Founded 1947
CEO Chen Schor
Employees 86
Stock Exchange NASDAQ
Ticker Symbol ACET
Full Company Profile

Financial Performance

In 2021, Adicet Bio's revenue was $9.73 million, a decrease of -45.65% compared to the previous year's $17.90 million. Losses were -$62.00 million, 69.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for ACET stock is "Buy." The 12-month stock price forecast is 28.65, which is an increase of 41.90% from the latest price.

Price Target
$28.65
(41.90% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients w...

REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, t...

3 days ago - Business Wire

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, t...

4 days ago - Business Wire

Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit

REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, t...

5 days ago - Business Wire

Wall Street Analysts Think Adicet Bio, Inc. (ACET) Could Surge 72%: Read This Before Placing a Bet

The mean of analysts' price targets for Adicet Bio, Inc. (ACET) points to a 71.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a...

6 days ago - Zacks Investment Research

Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer

REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, t...

6 days ago - Business Wire

If we do enter a recession next year, we'll see more of a rotation into health care, says RTW's Wong

Dr. Rod Wong, RTW Investments managing partner and CIO, joins the 'Halftime Report' to discuss his thoughts on the biotech sector going into the new year, his investing thesis behind Avidity Biosciences...

Other symbols: MATXRNA
2 weeks ago - CNBC Television

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

Here is how Adicet Bio, Inc. (ACET) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.

3 weeks ago - Zacks Investment Research

Wall Street Analysts See a 39% Upside in Adicet Bio, Inc. (ACET): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 38.7% in Adicet Bio, Inc. (ACET). While the effectiveness of this highly sought-after metric is questionable, the...

3 weeks ago - Zacks Investment Research

Adicet Bio, Inc. (ACET) Reports Q3 Loss, Misses Revenue Estimates

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 5.36% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference

REDWOOD CITY, Calif.

1 month ago - Business Wire

Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immuno...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first in class, allogeneic chimeric antigen receptor (C...

2 months ago - Business Wire

Adicet Bio to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen ...

2 months ago - Business Wire

Adicet Bio, Inc. (ACET) Reports Q2 Loss, Misses Revenue Estimates

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -24.44% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR T cell therap...

3 months ago - Business Wire

7 Cheap Biotech Stocks to Buy Now

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

4 months ago - InvestorPlace

Adicet Bio, Inc. (ACET) Is a Great Choice for "Trend" Investors, Here's Why

Adicet Bio, Inc. (ACET) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

4 months ago - Zacks Investment Research

Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year?

Here is how Adicet Bio, Inc. (ACET) and Catalyst Biosciences, Inc. (CBIO) have performed compared to their sector so far this year.

4 months ago - Zacks Investment Research

Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen ...

5 months ago - Business Wire

Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin's Lymphoma ...

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen re...

6 months ago - Business Wire

Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen re...

6 months ago - Business Wire

Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited ...

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen re...

7 months ago - Business Wire

Adicet Bio, Inc. (ACET) Surges 6.8%: Is This an Indication of Further Gains?

Adicet Bio, Inc. (ACET) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre...

7 months ago - Zacks Investment Research